Total Funding
53
27
Total FundingSeries A raised
Growth Score
-2 pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
39278
Ottimo Pharma develops innovative cancer therapies using PD1-VEGFR2 antibodies.
- Kathryn Golden: Vice President Technical OperationsPast Role: bit.bio, Senior Vice President, Technical Operations and Cell Manufacturing
- David Epstein: Chief Executive OfficerPast Role: Seagen, Chief Executive Officer & Director
About the Company
Ottimo Pharma focuses on creating pioneering cancer treatments for solid tumors, specifically through its lead program, Jankistomig, a bi-functional antibody targeting immune checkpoints and angiogenesis. The company aims to enhance treatment outcomes and alleviate healthcare burdens by advancing this dual-pathway approach.
